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http://dx.doi.org/10.1016/j.kjms.201Abstract A prominent factor in hepatocellular carcinoma (HCC) is chronic infection with hep-
atitis B virus (HBV) and hepatitis C virus (HCV). Diabetes mellitus (DM), metabolic syndrome
(MetS), and obesity have also been implicated in HCC development, but these associations
are not observed in all HBV- and HCV-endemic areas. We attempted to clarify the role of these
factors in HCC development in an HBV- and HCV-endemic area in southern Taiwan.
A community-based health examination was conducted in 2004 in Tainan County. After individ-
uals with incomplete data and those with known HCC were excluded, there were 56,231 par-
ticipants who were over 40 years of age. A further 262 HCC cases were identified from the
National Cancer Registration Database records from 2005 to 2007. The hepatitis B surface an-
tigen (HBsAg) seropositivity, anti-HCV seropositivity, platelet count, serum biochemical data,
blood pressure, sociodemographic information, and anthropometric measurements were ana-
lyzed. Survival analyses were used to identify the associations between these factors and HCC.
For the 262 HCC cases, male gender and age greater than 65 years were risk factors. Further-
more, a high alanine aminotransferase level, chronic HBV and/or HCV infection, and liver cir-
rhosis were also risk factors for HCC. However, DM, MetS and obesity were not associated withepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital,
Kaohsiung City 833, Taiwan.
.net (S.-N. Lu).
hsiung Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
2.12.006
452 C.-T. Chen et al.HCC development in the non-HBV-/non-HCV-infected, HBV, HCV, or dual B/C groups. In this
HBV- and HCV- endemic area, DM, MetS and obesity were not risk factors for developing HCC.
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The major etiology of hepatocellular carcinoma (HCC) is
chronic infection with hepatitis B virus (HBV) and hepatitis
C virus (HCV) in Taiwan and most other countries [1].
However, alcoholism, diabetes mellitus (DM) and obesity,
which are growing problems in the developed world [2,3],
have also been reported to be risk factors for HCC [4e6].
Indeed, in countries with a relatively low prevalence of
hepatitis B and C infection, DM has been shown to be
a significant contributor to the development of HCC [7,8].
In Taiwan, a westernized country with high HBV- and
HCV-endemic areas, at least five published cohort studies
have reported discrepant results [9e13]. However, these
studies were conducted in different geographical locations
on different populations, so no definite conclusion can be
drawn regarding the risk of HCC for obese or diabetic in-
dividuals. Although it is relatively well documented that
diabetic non-HBV-/non-HCV-infected (NBNC) patients have
an elevated risk of HCC, the impact of DM or obesity on the
incidence of HCC in individuals infected with HBV and HCV
remains unclear. Our previous cross-sectional case-con-
trolled studies revealed that DM and obesity did not sig-
nificantly influence HCC development in a dual HBV- and
HCV-endemic area [14]. The present cohort study attemp-
ted to further our understanding of the chronological
relationship between these factors, as well as to validate
the findings of our previous study.Patients and methods
The background of the study and inclusion and
exclusion criteria
In Taiwan, the prevalence of HBV and anti-HCV is 17.3% and
4.4%, respectively [15]. Tainan, located in southern Taiwan,
has a high rate of chronic hepatitis C among HCC cases, and
the numbers are still increasing [16]. A health examination
and cancer screening program was conducted by the Tainan
County Health Bureau from April to November 2004. There
were 56,702 participants, all of whom were over 40 years of
age. The participants were recruited by mail, telephone or
mass media. Of these, 366 individuals lacked data regarding
platelet count, lipid level and anthropometric measures.
Therefore, the participants comprised 17,440 males and
38,896 females, and the mean age was 60.9  11.8 years.
Furthermore, 105 individuals had HCC, as detected by
cancer screening. These persons were excluded from the
study. After excluding patients with incomplete informa-
tion and those with HCC, 56,231 subjects were enrolled. In
addition, we searched the National Cancer RegistrationDatabase records from 2005 to 2007 in order to find primary
liver cancer cases using the International Code of Disease-9
(ICD-9). Because HCC developed within 6 months or less,
these cases were newly diagnosed patients who did not
have HCC at the beginning of the study. We found 262 such
HCC cases: 145 men (55.3%) and 117 women (44.7%). The
mean age was 66.8  8.7 years. The entire study was
reviewed by the Institutional Review Board (IRB) at Chang
Gung Memorial Hospital. Informed consent was obtained
from all participants.
Study parameters and patient grouping
We analyzed the participants in terms of demographics (i.e.,
age and gender), anthropometrics (i.e., body weight and
height), hemodynamic information (i.e., systolic and dia-
stolic blood pressure), and serum biochemical data (i.e.,
alanine transaminase (ALT), high-density lipoprotein cho-
lesterol (HDL-C), triglyceride (TG), albumin (A), globulin
(G), and fasting glucose levels), as well as platelet count.
This information was obtained from all patients, and they
underwent a detailed work-up for serum hepatitis markers,
including hepatitis B surface antigen (HBsAg), anti-HCV, and
alpha-fetoprotein (AFP) at the time of enrollment in the
study. Enzyme-linked immunosorbent assay (ELISA) was used
to detect HBsAg and anti-HCV, using the SP-NANBASE C-96
3.0 plate machine (General Biological Corp., Hsinchu,
Taiwan). We performed biochemical tests using the Hitachi
747 automatic analyzer (Hitachi, Tokyo, Japan).We checked
platelet counts using the Sysmex SE9000 analyzer (Sysmex
UK, Milton Keynes, UK). All recruited patients were divided
into four groups according to their status of viral hepatitis
infection: NBNC, HBV, HCV and dual B/C. DM was defined as
a fasting blood sugar level >126 mg/dL, which was the cri-
terion recommended by the American Diabetes Association
in 1997. Obesity was defined as a body mass index (BMI) of
>27 kg/m2. Metabolic syndrome (MetS) was defined as the
fulfillment of at least three of the following criteria: (1)
abdominal obesity (waist: males  90 cm, females  80 cm,
or BMI > 27 kg/m2); (2) blood pressure [systolic pressure
(SBP)  130 mmHg or diastolic pressure (DBP)  85 mmHg];
(3) hyperglycemia [fasting glucose (FG)  100 mg/dL]; (4)
HDL-C (males < 40 mg/dL, females < 50 mg/dL); and (5)
TG  150 mg/dL [17]. Individuals were diagnosed with
hepatitis if their ALT level exceeded 40 IU/L. An A/G ratio
reverse of 1 and platelet count of less than 150  103/mL
were considered markers of severe liver fibrosis.
Statistical analysis
Average values are expressed as mean  SD. Survival
analysis was performed using KaplaneMeier survival
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Log-rank tests were used to compare the cumulative inci-
dence of HCC with different factors such as DM, MetS, and
obesity among different viral hepatitis states. The Cox
proportional hazard model was used to estimate the uni-
variate and multivariate effects of the different risks with
time with regard to the incidence of HCC. Hazard ratios
(HR) and 95% confidence intervals (CI) were used to
describe the strength of the association between risk fac-
tors and HCC. A p value <0.05 was considered statistically
significant.
Results
Demographics, anthropometrics, hepatitis profile,
and laboratory data of the study population
A total of 56,231 individuals were recruited into the study.
Demographic, anthropometric and relevant laboratory in-
formation is shown in Table 1. The numbers of participants
were 44,941 (79.92%), 5606 (9.96%), 5186 (9.22%), and 498
(0.88%) NBNC, HBV, HCV, and dual B/C, respectively.
Of the 262 patients who subsequently developed HCC,
more than one-half were males (n Z 145, 55.3%), most
were older than 65 years (nZ 169, 64.5%), and their mean
age was 66.8  8.7 years. Prevalence of DM, MetS and
obesity was found in 34 (13.0%), 38 (14.5%), and 62 (23.7%)
patients, respectively. Furthermore, 21.8% (n Z 57) of the
participants were HBsAg positive, and 159 (60.7%) were
positive for anti-HCV. NBNC infection was noted in 31
patients (11.8%), whereas dual B/C infection was found in
15 patients (5.7%).
Impact of DM, MetS, and obesity on the cumulative
incidence rate of HCC
The variation of MetS with the cumulative incidence rate of
HCC for different viral hepatitis states is shown in Fig. 1. We
divided the participants into four groups (NBNC, HBV, HCV,
and dual B/C). Among HBV patients, the cumulative inci-
dence rate of HCC increased with time, as depicted by the
KaplaneMeier survival analysis. At the same time, partic-
ipant data were analyzed using the log-rank test; we found
no significant difference in the risk for HCC development
with the MetS variable (p Z 0.583). We also analyzed the
incidence of HCC among the HCV, NBNC and dual B/C
groups and found no difference between MetS and non-MetS
patients in terms of their risk for HCC development.
Similarly, DM and obesity were found to play no role in HCC
development (Figs. 2 and 3).
Comparison of the risk of HCC among individuals
with different viral status with MD, MetS, and
obesity
The risk factors of HCC development were analyzed using
the Cox proportional hazard model (Table 1). The results of
univariate analysis showed that males were at a higher risk
for HCC. Age over 65 years, viral hepatitis status, ALT levels
higher than the upper limit of normal, an A/G ratio of lessthan 1, and a platelet count less than 150  103/mL were
also associated with the occurrence of HCC (p < 0.001 in all
cases). However, no statistically significant correlation was
noted with DM or obesity. However, MetS was shown to
carry an elevated risk of HCC (pZ 0.004). The multivariate
analysis of independent variables was undertaken in
Models 1 and 2. In Model 1, male gender, advanced age
and hepatitis were all significant risks for HCC develop-
ment. However, DM, MetS and obesity exhibited no signifi-
cant association with the risk of HCC. In Model 2, while
we considered the risk factors of liver cirrhosis
(ALT level > 40 IU/L, A/G ratio  1, and platelet
count < 150  103/mL), the results were incidental.
The impact of viral hepatitis status on HCC development
was subsequently analyzed. In the NBNC group, the factors
of old age, A/G reverse, and thrombocytopenia were sig-
nificantly associated with the occurrence of HCC in multi-
variate analysis. In particular, old age was a significant risk
factor in this group but not in other groups (Table 2). In
patients with hepatitis B, gender, ALT level, A/G ratio and
platelet count were associated with the development of
HCC in multivariate analysis (Table 2). In the hepatitis C
group, the results of the analysis were similar to those seen
for hepatitis B patients (Table 3). The HR for males was 7.23
(95% CI, 3.56e14.70) in the chronic HBV group, triple that
of the HCV group (HRZ 2.05; 95% CI, 1.46e2.87). However,
univariate analysis of the dual B/C group revealed that
male gender, reduced A/G ratio and decreased platelet
count were significantly correlated with a higher risk of HCC
development. However, the risk factors that did not impact
on HCC development in this group were old age and ALT
level, as revealed by the multivariate analysis (Table 3). We
found that DM, MetS, and obesity were not significant risk
factors for HCC, regardless of viral hepatitis status (Tables 2
and 3).Discussion
In this cohort study, we found that DM, MetS, and obesity in
individuals regardless of status of HBV or HCV did not
impact on the development of HCC in the hepatitis B- and
C-endemic area. Among those infected with viral hepatitis,
the risk factors for HCC were male gender, hepatitis and
liver cirrhosis However, only old age and liver cirrhosis were
significant risk factors for the NBNC group.
Chronic HBV and HCV infection worldwide has a preva-
lence of 350 and 170 million cases, respectively [18].
Meanwhile, this study mentioned that the incidence of
primary liver cancer has decreased in some developing
countries because the HBV vaccine is being recommended.
The percentage of HBV-related HCC has progressively
decreased. In contrast, HCV-related HCC has continuously
increased, because of acquired HCV infections two to four
decades ago, and incidents are likely to continue increasing
over the next decade [19]. Among Asian countries, a similar
trend has been observed in Japan [20] and Taiwan [16]. In
Taiwan, the HBV carrier rate and childhood HBV-related
HCC have dramatically decreased ever since a mass vacci-
nation program was implemented in 1984 [21]. Over the
past 20 years, our previous study showed that the per-
centage of HBV-related HCC cases has progressively
Table 1 Selected risk factors for incident HCC and variate analyses.
Variable HCC Control Univariate Multivariate (m dule 1) Multivariate (module 2)
n Z 262 (%) n Z 55969 (%) HR (95% CI) p HR (95% CI) p HR (95% CI) p
Sex Female 117 (0.3) 38,733 (99.7) 1 1 1
Male 145 (0.8) 17,236 (99.2) 2.79 (2.18e3.56) <0.001 2.73 (2.13e3.50) <0.001 2.80 (2.15e3.65) <0.001
Age (y) <65 93 (0.3) 33,059 (99.7) 1 1 1
65 169 (0.7) 22,910 (99.3) 2.62 (2.04e3.38) <0.001 2.04 (1.57e2.65) <0.001 1.60 (1.21e2.12) 0.001
Hepatitis NBNC 31 (0.1) 44,910 (99.9) 1 1 1
B 57 (1.0) 5549 (99.0) 14.88 (9.60e23.07) <0.001 15.76 (10.15e24.4 ) <0.001 10.35 (6.59e16.27) <0.001
C 159 (3.1) 5027 (96.9) 45.82 (31.15e67.40) <0.001 44.03 (29.89e64.8 ) <0.001 10.40 (6.71e16.14) <0.001
Dual B/C 15 (3.0) 483 (97.0) 44.99 (24.13e83.88) <0.001 46.29 (24.76e86.5 ) <0.001 14.58 (7.38e28.80) <0.001
ALT (IU/L) 40 88(0.2) 48,981 (99.8) 1 1
>40 174 (2.4) 6988 (97.6) 13.86 (10.71e17.93) <0.001 2.68 (1.96e3.66) <0.001
A/G ratio >1 130 (0.2) 54,834 (99.8) 1 1
1 132 (10.4) 1135 (89.6) 49.06 (38.23e62.94) <0.001 9.12 (6.77e12.28) <0.001
PLT (103, mm3) >150 111 (0.2) 52,252 (99.8) 1 1
150 151 (3.9) 3717 (96.1) 19.12 (14.93e24.49) <0.001 3.07 (2.30e4.11) <0.001
DM Non-DM 228 (0.4) 50,628 (99.6) 1
DM 34 (0.6) 5341 (99.4) 1.41 (0.99e2.03) 0.061 d d d
Obesity Non-obesity 200 (0.5) 42,493 (99.5) 1
Obesity 62 (0.5) 13,476 (99.5) 0.98 (0.74e1.30) 0.876 d d d
MetSa Non-MetS 224 (0.5) 43,660 (99.5) 1
MetSa 38 (0.3) 12,309 (99.7) 0.60 (0.43e0.85) 0.004 d d d
A Z albumin; ALT Z alanine transaminase; CI Z confidence interval; DM Z diabetes mellitus; G Z globulin; HCC Z hepatocellular arcinoma; HR Z hazard ratio; MetS Z metabolic
syndrome; NBNC Z non-HBV-/non-HCV-infected; PLT Z platelet.
a MetS was defined as the fulfillment of at least three of the following criteria: (1) abdominal obesity (waist: males  90 cm, femal  80 cm, or BMI > 27 kg/m2); (2) blood pressure
[systolic pressure (SBP)  130 mmHg or diastolic pressure (DBP)  85 mmHg]; (3) hyperglycemia [fasting glucose (FG)  100 mg/dL]; (4 HDL-C (males < 40 mg/dL, females < 50 mg/dL);
and (5) TG  150 mg/dL [17,48].
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Figure 3. Survival analysis and log-rank test of the devel-
opment of hepatocellular carcinoma (HCC) and obesity in in-
dividuals with different viral infection state from 2005 to 2007.
HBVZ hepatitis B virus; HCVZ hepatits C virus; NBNCZ non-
HBV-/non-HCV-infected.
Figure 1. Survival analysis and log-rank test of the devel-
opment of hepatocellular carcinoma (HCC) and metabolic
syndrome (MetS) in people with different viral infection state
from 2005 to 2007. HBVZ hepatitis B virus; HCVZ hepatitis C
virus; NBNC Z non-HBV-/non-HCV-infected.
DM or metabolic syndrome associated with HCC? 455decreased [16]. In contrast, the percentage of HCV-related
HCC cases has increased. Our study area (Tainan), which is
located in southern Taiwan, had a higher prevalence of HCV
[22,23], and there were 159 (60.7%) cases of HCV infection,
which was similar to our previous investigation.
Thrombocytopenia was a surrogate of hepatic fibrosis in
patients infected with HCV [24,25], and it was the most
common abnormal hematological anomaly occurring in pa-
tients with cirrhosis [26]. Therefore, underlying cirrhosisFigure 2. Survival analysis and log-rank test of the devel-
opment of hepatocellular carcinoma (HCC) and type 2 diabetes
mellitus (DM) in individuals with different viral infection state
from 2005 to 2007. HBV Z hepatitis B virus; HCV Z hepatits C
virus; NBNC Z non-HBV-/non-HCV-infected.appears to be a risk factor for HCC development. In our
study, thrombocytopenia was a risk factor for HCC devel-
opment, and the HR was 3.07 (95% CI: 2.30e4.11). We
analyzed this factor and obtained identical results. The HR
in the NBNC, HBV, HCV and the dual B/C groups was 8.83
(4.17e18.68), 3.22 (1.78e5.82), 2.47 (1.72e3.55) and 6.36
(1.86e21.75), respectively. An elevated ALT level also
indicated hepatitis, and it was a risk factor for HCC in
a previous community study in an HCV-endemic area
[27,28]. However, the hepatitis activity in HBV infection
was substantially less than in chronic HCV infection because
high ALT levels occur in patients with chronic HBV infection
in the immune clearance phase; this is primarily observed in
individuals under 40 years of age [29]. However, all our
participants were over 40 years old, and the HR of hepatitis
B patients was 3.04 (1.70e5.43). The HR for the hepatitis
C group was 2.20 (1.46e3.31), but there were no such
associations in the NBNC and dual B/C groups.
DM and obesity are risk factors for HCC, as known from
epidemiology studies [7], and people with diabetes are
reported to have about a 2.5-fold relative risk of develop-
ment of HCC [30]. In hepatitis-endemic countries, partic-
ularly those in the East, whether DM is an independent risk
factor of HCC development remains uncertain [31]. In Tai-
wan, there is still no definitive conclusion concerning the
impact of DM and obesity on HCC [9e13]. The diagnosis of
DM should also include blood sugar  126 mg/dL at separate
times, but this was difficult to confirm in this large
community-based study. The prevalence of DM in our study
was 9.6%, which was slightly lower than that in the northern
Taiwan study [9], where it was reported to be about 10.4%.
However, participants were enrolled when they were over
40 and 30 years of age, respectively. In the cross-sectional
and case-controlled study, we defined DM as a blood sugar
level of  140 mg/dL, and we found that DM had no
Table 2 Selected risk factors of incident HCC in the NBNC and HBV carrier groups.
Variable HCC Control Univariate Multivariate
HR (95% CI) p HR (95% CI) p
NBNC group n Z 31 (%) n Z 44910 (%)
Sex Female 13 (41.9) 31,116 (69.3) 1
Male 18 (58.1) 13,794 (30.7) 3.12 (1.53e6.38) 0.002 d d
Age (y) <65 5 (16.1) 26,488 (59.0) 1 1
65 26 (83.9) 18,422 (41.0) 7.48 (2.87e19.47) <0.001 4.77 (1.79e12.69) 0.002
ALT (IU/L) 40 24 (77.4) 40,913 (91.1) 1
>40 7 (22.6) 3997 (8.9) 2.99 (1.29e6.93) 0.011 d d
A/G ratio >1 23 (74.2) 44,411 (98.9) 1 1
1 8 (25.8) 499 (1.1) 30.96 (13.78e69.54) <0.001 13.16 (5.63e30.77) <0.001
PLT(103, mm3) >150 18 (58.1) 43,006 (95.8) 1 1
150 13 (41.9) 1904 (4.2) 16.31 (7.98e33.34) <0.001 8.83 (4.17e18.68) <0.001
DM Non-DM 26 (83.9) 40,589 (90.4) 1
DM 5 (16.1) 4321 (9.6) 1.81 (0.69e4.71) 0.226 d d
Obesity Non-obesity 26 (83.9) 34,109 (75.9) 1
Obesity 5 (16.1) 10,801 (24.1) 0.61 (0.23e1.58) 0.307 d d
MetS Non-MetS 27 (87.1) 34,574 (77.0) 1
MetS 4 (12.9) 10,336 (23.0) 0.50 (0.17e1.42) 0.190 d d
HBV carrier group n Z 57 (%) n Z 5549 (%)
Sex Female 10 (17.5) 3676 (66.2) 1 1
Male 47 (82.5) 1873 (33.8) 9.22 (4.65e18.30) <0.001 7.23 (3.56e14.70) <0.001
Age (y) <65 29 (50.9 3881 (69.9) 1
65 28 (49.1) 1668 (30.1) 2.25 (1.33e3.79) 0.002 d d
ALT (IU/L) 40 26 (45.6) 4743 (85.5) 1 1
>40 31 (54.4) 806 (14.5) 7.02 (4.14e11.88) <0.001 3.04 (1.70e5.43) <0.001
A/G ratio >1 38 (66.7) 5453 (98.3) 1 1
1 19 (33.3) 96 (1.7) 28.40 (15.80e51.06) <0.001 13.10 (6.78e25.30) <0.001
PLT (103, mm3) >150 31 (54.4) 5040 (90.8) 1 1
150 26 (45.6) 509 (9.2) 8.31 (4.89e14.10) <0.001 3.22 (1.78e5.82) <0.001
DM Non-DM 50 (87.7) 5106 (92.0) 1
DM 7 (12.3) 443 (8.0) 1.61 (0.73e3.58) 0.239 d d
Obesity Non-obesity 45 (78.9) 4215 (76.0) 1
Obesity 12 (21.1) 1334 (24.0) 0.84 (0.44e1.60) 0.600 d d
MetS Non-MetS 45 (78.9) 4535 (81.7) 1
MetS 12 (21.1) 1014 (18.3) 1.19 (0.63e2.26) 0.590 d d
A Z albumin; ALT Z alanine transaminase; CI Z confidence interval; DM Z diabetes mellitus; G Z globulin; HCC Z hepatocellular
carcinoma; HR Z hazard ratio; MetS Z metabolic syndrome; NBNC Z non-HBV-/non-HCV-infected; PLT Z platelet.
456 C.-T. Chen et al.significant impact [14]. In this cohort study, the results
were validated. DM, MetS, and obesity did not increase the
incidence of HCC.
The mechanisms by which DM induces HCC are related to
insulin-like growth factor I (IGF-I) or insulin-like growth
factor-binding protein-3 (IGFBP-3) [32]. An epidemiological
study reported that diabetic and overweight individuals are
likely to develop nonalcoholic fatty liver disease and more
severe nonalcoholic steatohepatitis (NASH). These diseases
might cause liver fibrosis and cirrhosis, which is called
“cryptogenic cirrhosis” in terms of histological features.
More recent studies report that it will result in the devel-
opment of NASH-associated HCC [33]. However, in countries
where viral hepatitis is not widespread, DM and obesity
have a low impact on the incidence of HCC. One Italian
study reported less than 7% of HCC cases could be attrib-
uted to cryptogenic cirrhosis [34]. Another study of liver
transplantation patients reported 1207 cases of HCC amongindividuals who were screened. There were only 31 cases
(2.6%) of HCC with NASH as the primary cause of liver dis-
ease, and 16 cases (2.9%) with end-stage liver disease
secondary to NASH [35]. In Taiwan, however, nearly 90% of
HCC cases are related to HBV or HCV infection, and these
results in HCC development after 30e40 years or even
longer. It seems less likely for diabetic or overweight pa-
tients to develop cirrhosis or HCC without concomitant viral
hepatitis or liver disease within a few years.
With regard to the BMI value, we considered 27 as the
cut-off point, which was different from that in a previous
study [14] and in the northern Taiwan study [9]. The BMI
values in those studies were 25 and 24, respectively.
However, we consistently found that obesity was not a sig-
nificant risk factor for HCC, although body weight affected
the development of HCC in different areas or at different
cut-off points, especially in the West [36]. A prospective
cohort study found an association between body weight and
Table 3 Selected risk factors of incident HCC in the HCV carrier and dual B/C groups.
Variable HCC Control Univariate Multivariate
HR (95% CI) p HR (95% CI) p
HCV carrier group n Z 159 (%) n Z 5027 (%)
Sex Female 88 (55.3) 3604 (71.7) 1 1
Male 71 (44.7) 1423 (28.3) 2.04 (1.49e2.81) <0.001 2.05 (1.46e2.87) <0.001
Age (y) <65 53 (33.3) 2406 (47.9) 1
65 106 (66.7) 2621 (52.1) 1.84 (1.31e2.57) <0.001 d d
ALT (IU/L) 40 123 (77.4) 2000 (39.8) 1 1
>40 36 (22.6) 3027 (60.2) 5.17 (3.55e7.53) <0.001 2.20 (1.46e3.31) <0.001
A/G ratio >1 60 (37.7) 4516 (89.8) 1 1
1 99 (62.3) 511 (10.2) 14.58 (10.45e20.35) <0.001 8.86 (6.20e12.68) <0.001
PLT (103, mm3) >150 58 (36.5) 3833 (76.2) 1 1
150 101 (63.5) 1194 (23.8) 5.59 (4.02e7.77) <0.001 2.47 (1.72e3.55) <0.001
DM Non-DM 137 (86.2) 4496 (89.4) 1
DM 22 (13.8) 531 (10.6) 1.36 (0.86e2.15) 0.190 d d
Obesity Non-obesity 117 (73.6) 3829 (76.2) 1
Obesity 42 (26.4) 1198 (23.8) 1.15 (0.80e1.64) 0.452 d d
MetS Non-MetS 138 (86.8) 4155 (82.7) 1
MetS 21 (13.2) 872 (17.3) 0.73 (0.46e1.15) 0.175 d d
Dual B/C group n Z 15 (%) n Z 483 (%)
Sex Female 6 (40.0) 337 (69.8) 1 1
Male 9 (60.0) 146 (30.2) 3.46 (1.21e9.91) 0.021 4.63 (1.45e14.77) 0.010
Age (y) <65 6 (40.0) 284 (58.8) 1
65 9 (60.0) 199 (41.2) 2.14 (0.75e6.11) 0.155 d d
ALT (IU/L) 40 2 (13.3) 298 (61.7) 1
>40 13 (86.7) 185 (38.3) 10.47 (2.34e46.92) 0.002 d
A/G ratio >1 9 (60.0) 454 (94.0) 1 1
1 6 (40.0) 29 (6.0) 10.44 (3.48e31.33) <0.001 7.36 (2.12e25.60) 0.002
PLT (103, mm3) >150 4 (26.7) 373 (77.2) 1 1
150 11 (73.3) 110 (22.8) 9.33 (2.91e29.86) <0.001 6.36 (1.86e21.75) 0.003
DM Non-DM 15 (100) 437 (90.5) 1
DM 0 46 (9.5) d 0.998 d d
Obesity Non-obesity 12 (80.0) 340 (70.4) 1
Obesity 3 (20.0) 143 (29.6) 0.59 (0.17e2.14) 0.426 d d
MetS Non-MetS 14 (93.3) 396 (82.0) 1
MetS 1 (6.7) 87 (18.0) 0.33 (0.04e2.51) 0.281 d d
A Z albumin; ALT Z alanine transaminase; CI Z confidence interval; DM Z diabetes mellitus; G Z globulin; HCC Z hepatocellular
carcinoma; HR Z hazard ratio; MetS Z metabolic syndrome; NBNC Z non-HBV-/non-HCV-infected; PLT Z platelet.
DM or metabolic syndrome associated with HCC? 457cancer [37]. It revealed that a BMI value of  35 kg/m2 in
men significantly elevated the relative risk of death
from cancer. These results were similar for women
(BMI  40 kg/m2). However, only 1.09% of participants had
a BMI value of over 35 kg/m2 in our study. Therefore, the
association between BMI and HCC development must be
considered in light of the differences between the East and
West, or Orientals and Occidentals.
This study has several limitations. First, abdominal
girth was used instead of BMI because it is difficult to
measure BMI in a large community-based health study.
Although the correct method for determining abdominal
girth is to measure the length between the lowest rib
margin and iliac crest and keep the tape horizontal, some
behavioral bias might have occurred. In keeping with the
recommendation of the International Obesity Task Force,
central obesity was defined as an abdominal girth of 90 cm
for men and 80 cm for women in the AsiaePacific
area [38]. In Taiwan, this is similar to the standard value inthe AsiaePacific region, where the BMI value is 27 kg/m2
on average [39]. Therefore, we substituted it for
abdominal girth. Second, in this large-scale community
study, we can only define patients with fasting blood sugar
higher than 126 mg/dL as cases of DM. However, some DM
patients who were well controlled may have not been
detected by the current study. Others who had only one
situation of high blood sugar level may have been included
as a case. Therefore, if we undertake similar study in the
future, we will conduct a questionnaire of medical history
as well as checking HbA1c to reduce bias. Finally, we were
unable to obtain pathology reports, and it was difficult to
undertake comprehensive active surveillance in a large
community study.
In conclusion, DM, MetS and obesity are not significant
risk factors for HCC in the HBV and HCV-endemic area of
focus in this cohort study. In the future, we plan to follow
up the participants of this study in order to elucidate the
compatibility with our previous studies.
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